Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia

Matthew J Cross, MBBS, BSc, Paras Shah, MPHARM, Kara Heelan, MBBCh, BAO, MD, Claire E. Dearden, MD FRCP, FRCPath, Dima El-Sharkawi, MBBS, FRCPath, PhD, Sunil Iyengar, MBBS, FRCPath, PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137531

Published: 2020

Journal Articles

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

Matthew J Cross, MBBS, BSc, Grzegorz Pietka, PhD, Sarah Dunne, Leonora Conneely, Michael Hubank, PhD, Corinne De Lord, MD FRCPath, Michelle Furtado, MD FRCPath, PhD, Pawel Kaczmarek, MD PhD, Dima El-Sharkawi, Claire E. Dearden, MD FRCP, FRCPath, Kabir Mohammed, Alan Stewart Dunlop, MSc, BS, Ricardo Morilla, Karol Pal, PhD, Nikos Darzentas, PhD, David Gonzalez, PhD, Dorte Wren, PhDFRCPath, Sunil Iyengar, MD FRCPath, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141542

Published: 2020

Journal Articles

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Matthew J Cross, MBBS, BSc, Monica Else, Ricardo Morilla, Mark Edward Ethell, MD, Michael Potter, MD, Dima El-Sharkawi, Sunil Iyengar, MBBS, FRCPath, PhD, Claire E. Dearden, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 1552.

https://doi.org/10.1182/blood-2019-122094

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma

Charlotte Wilding, BSc, MBChB, Farheen Mir, MBBS, Indu Mitra, Bhupinder Sharma, Larissa Sena, Andrew Wotherspoon, David Cunningham, MD FRCP, Ian Chau, MD, Claire E. Dearden, MD FRCP, FRCPath, Kabir Mohammed, Sunil Iyengar

Blood (2017) 130 (Supplement 1): 2786.

https://doi.org/10.1182/blood.V130.Suppl_1.2786.2786

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD

Blood (2010) 116 (21): 697.

https://doi.org/10.1182/blood.V116.21.697.697

Published: 2010

Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 60.

https://doi.org/10.1182/blood.V116.21.60.60

Published: 2010

Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock

Blood (2009) 114 (22): 3428.

https://doi.org/10.1182/blood.V114.22.3428.3428

Published: 2009

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.

Mauricette Michallet, MD, PhD, Peter Dreger, MD, PhD, Laurent Sutton, MD, Ronald Brand, Sue Richards, Anja van Biezen, Mohamad Sobh, Pharm.M, Alois Gratwohl, MD, Karin Kolbe, MD, Claire E. Dearden, MD, Michael Hallek, T. M. de Witte, MD, PhD, Dietger W. Niederwieser, MD, Michel Leporrier, MD, Donald Milligan, MD

Blood (2009) 114 (22): 877.

https://doi.org/10.1182/blood.V114.22.877.877

Published: 2009

Journal Articles

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Ami t S Khot, Estella Matutes, MD, PhD, Pawel A Kaczmarek, Mike Hamblin, Ashok Roy, Effie Grand, Mark E Ethell, Claire E Dearden, MD

Blood (2008) 112 (11): 4204.

https://doi.org/10.1182/blood.V112.11.4204.4204

Published: 2008

Journal Articles

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Sarah L Hockley, PhD, David Gonzalez, PhD, Vasantha Brito-Babapulle, PhD, Monica Else, MA, MSc, Paola E Leone, Brian A Walker, Estella Matutes, MD, PhD, Claire E Dearden, MD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 3140.

https://doi.org/10.1182/blood.V112.11.3140.3140

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

The Combination of Fludarabine and Cyclophosphamide Has a Beneficial Effect on the Incidence of Hemolytic Anemia in Chronic Lymphocytic Leukemia. Results from the UK LRF CLL4 Trial.

Claire E. Dearden, MD, Rachel L. Wade, MSc, Monica Else, MSc, Sue M. Richards, DPhil, Don W. Milligan, MD, Terry J. Hamblin, MD, Daniel Catovsky, DSc

Blood (2007) 110 (11): 2044.

https://doi.org/10.1182/blood.V110.11.2044.2044

Published: 2007

NARROW

Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

The Combination of Fludarabine and Cyclophosphamide Has a Beneficial Effect on the Incidence of Hemolytic Anemia in Chronic Lymphocytic Leukemia. Results from the UK LRF CLL4 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only